Articles tagged "Kidney/liver transplantation"

2019 American Transplant Congress
AMD3100 and Low-Dose FK506 Prevent De Novo Donor Specific Antibody Formation and Rejection in a Sensitized Kidney Transplantation Model
A. R. Ahmadi, L. Qi, R. N. Wesson, A. M. Cameron, Z. Sun
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: De novo donor specific antibody (DSA) formation and antibody mediated rejection (AMR) are the main cause of allograft failure long-term. We have developed a…
2019 American Transplant Congress
HOPE Act Deceased Donors Referrals: Barriers to Donation
O. Kusemiju, C. Durand, B. Doby, M. Bowring, B. Barnaba, W. Werbel, D. Brown, A. Tobian, S. Seaman, D. Ostrander, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: HIV+ deceased donors (D+) represent a unique resource for HIV+ recipients but HIV D+ may have medical contraindications to donation or lower authorization rates.…
2019 American Transplant Congress
Stakeholder Perspectives in Peer Mentoring Program for Pediatric Solid Organ Transplant Recipients
C. Strachan, M. Paton, J. Reason, S. Amaral
Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA
*Purpose: This study analyzed feedback surveys from Peers4PATH, a peer mentoring program, aimed to improve medication adherence and health related quality of life (HRQOL) in…
2019 American Transplant Congress
Improved Transplant Outcomes in Ischemia-Free Liver Transplantation: A Report of the First 30 Cases
X. He, Z. Guo, W. Ju, Q. Zhao, S. Huang, J. Yang, L. Wang, Y. Tang, Z. Zhang, Z. Zhu, L. Yang, Y. Zhu, F. Gong, C. Cai, W. Huang, G. Chen, M. Chen, F. Ji, M. Han, A. Hu, L. Wu, Y. Ma, D. Wang, J. Huang, X. Li
Organ Transplant Center, the First Affiliated Hospital of SYSU, Guangzhou, China
*Purpose: We developed a novel procedure called ischemia-free liver transplantation (IFLT) to bridge liver grafts from donors to recipients without cessation of blood supply. Herein,…
2019 American Transplant Congress
Early Renal Allograft Failure after Simultaneous Liver-Kidney Transplantation: Evidence for Utilization of the Safety Net
G. Cullaro¹, E. C. Verna², B. J. Orandi³, J. C. Lai¹
¹UCSF, San Francisco, CA, ²Columbia University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL
*Purpose: Utilization of simultaneous liver-kidney transplant (SLKT) has increased dramatically during the Model for End-Stage Liver Disease (MELD) era. Prior studies have demonstrated a modest…
2019 American Transplant Congress
Type of Induction Does Not Impact Patient or Kidney Allograft Survival in Simultaneous Liver and Kidney Transplant Recipients in the United States
S. Riad¹, N. Lim², S. Jackson³, J. Lake²
¹University of Minnesota, Minneapolis, MN, ²Medicine, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, Fairview Health Services, Minneapolis, MN
*Purpose: Induction practices vary widely in the United States for patients undergoing simultaneous liver and kidney (SLK) transplantation. We examined the impact of induction type…
2019 American Transplant Congress
Human Neutrophil Function against Pathogens in Solid Organ and Stem Cell Transplant Recipients
N. Barros, N. Alexander, Z. Dagher, S. Knooihuizen, A. Viens, A. R. Hopke, D. Irimia, M. K. Mansour
Transplant Infectious Diseases, Massachusetts General Hospital, Boston, MA
*Purpose: The effects of solid organ (SOT) and allogeneic stem cell transplantation (SCT) on the neutrophil function is not well described. In this study, we…
2019 American Transplant Congress
Iguratimod Inhibits the Donor Specific Antibodies Production and Attenuates the Antibody Mediated Rejection in Rat Kidney Transplantation
Z. Wang, M. Zheng, H. Chen, S. Li, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: Our study was designed to investigate the efficacy and related mechanisms of Iguratimod (T-614) in the inhibition of DSAs following kidney transplantation.*Methods: A rat…
2019 American Transplant Congress
Outcomes for Liver Transplant Recipients on Renal Replacement Therapy: Who Cannot Wait for Safety Net
A. Pita¹, N. Kaur¹, M. Lo², A. F. Sabour¹, V. Tristan¹, Y. Genyk¹, M. K. Nadim³, L. Sher¹
¹Department of Surgery, Keck Medical Center of USC, Los Angeles, CA, ²Department of Preventive Medicine, Keck Medical Center of USC, Los Angeles, CA, ³Department of Medicine, Keck Medical Center of USC, Los Angeles, CA
*Purpose: The purpose of this study is to identify risk factors for poor outcomes for liver transplant (LT) recipients on renal replacement therapy (RRT) in…
2019 American Transplant Congress
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
J. A. Seaman¹, S. G. Westphal², F. Qiu³, D. Bremers⁴, D. Florescu⁵
¹College of Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Nephrology, University of Nebraska Medical Center, Omaha, NE, ³Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁴Donate Life, Nebraska Medicine, Omaha, NE, ⁵Internal Medicine Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE
*Purpose: The aim of our study was to compare the outcomes one-year after renal transplant with a focus on opportunistic infections in patients who received…